Drug details

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc injection)

type of Fc Receptor Antagonists

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) is a combination of a neonatal Fc receptor blocker and an endoglycosidase indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

The drug is often used to treat Myasthenia gravis .

This drug may have the following side effects:

• headache,
• urinary tract infection (UTI),
• muscle pain.
• respiratory tract infections,
• injection site reactions (rash, redness, itching, bruising, pain, and hives),
• numbness and tingling sensations, and

The following drugs are related to Vyvgart Hytrulo, either as a replacement or used together:

• Soliris (eculizumab)
• Vyvgart (efgartigimod alfa-fcab injection)
• Mestinon (pyridostigmine)
• Regonol (pyridos tigmine bromide injection)
• Ultomiris (ravulizumab-cwvz injection)
• Rystiggo (rozanolixizumab-noli injection)